Daicel Corporation

All figures are Japanese GAAP, consolidated, in JPY millions. Sources: Yuho FY2026/3 five-year summary; Tanshin FY2024/3 and FY2026/3. Gross profit, EBITDA and R&D for FY2022–FY2023 come from Envalith and Stockanalysis (aggregators). EBITDA is defined as operating profit plus depreciation and amortization; this matches Daicel's reported ¥102.4bn for FY2025.

Income statement

Diluted EPS equals basic EPS because Daicel has no dilutive securities (Yuho note).

Revenue CAGR was 5.5% from FY2022 to FY2026 (four years, derived). It was 8.0% from FY2021 (¥393.6bn) to FY2026 (five years, derived). Most of the growth came in FY2022–FY2023, driven by post-COVID recovery, the full consolidation of Polyplastics from October 2020, and yen depreciation.

Quarterly cadence, FY2026/3 and Q1 FY2027/3 (derived from cumulative disclosures):

Commentary.

FY2023: margin compression: Revenue rose 15% but operating profit fell 6.3%. Raw-material and energy inflation, plus automotive inventory corrections, outran price increases.

FY2024: peak profitability: Operating profit of ¥62.4bn and an 11.2% margin were driven by Materials. Acetate tow price corrections, demand for heated-tobacco tow and the weak yen lifted Materials OP 106% to ¥42.7bn.

FY2025: record EBITDA, flat operating profit: EBITDA reached ¥102.4bn as Engineering Plastics recovered. The CO-plant problem at Aboshi capped Materials, and new capacity raised depreciation by ¥7.7bn.

FY2026: inflection down: Operating profit fell 31% because Materials halved (inventory carryover, acetate tow destocking, FX) and Engineering Plastics absorbed depreciation and inspection costs. Net income collapsed 79% to ¥10.2bn after ¥32.8bn of impairments, of which about ¥32.4bn related to the TOPAS COC Plant No. 2 in Germany. Ongoing ¥17.5bn gains on cross-shareholding sales only partly offset the hit.

Earnings quality: Extraordinary gains from cross-shareholding sales of ¥11.2bn, ¥15.9bn and ¥17.5bn in FY2024–FY2026 flattered net income for three years. These gains are finite: the cross-shareholding sale plan totals ¥15bn over FY2027–FY2029 under Accelerate 2030.

Balance sheet

Notes on the balance sheet.

• FY2022 total debt is derived from the company's reported ratio of interest-bearing debt to operating cash flow (6.6 years × ¥42,993m). It is an approximation, not a disclosed figure.

• FY2024 net assets are shown as restated in the FY2026/3 Yuho (¥375,410m). The figure originally reported was ¥374,861m. The difference reflects the 2022 revised tax accounting standard.

• At 30 June 2026, total debt was ¥310.8bn, including ¥14.0bn of new commercial paper, and cash was ¥73.0bn. Inventories rose to ¥187.0bn.

Commentary. The balance sheet is conservatively geared for a capex-heavy chemical company. The equity ratio is about 43%, and net debt has held at roughly ¥215–240bn throughout the investment cycle. Goodwill is negligible at ¥52m in FY2026. The Polyplastics buyout was accounted for as a transaction with non-controlling interests, so no goodwill was booked; the effect showed up as a reduction in equity at the time. Two structural issues stand out:

1. Very high inventories of about ¥175–183bn, roughly 30% of sales, tied to the long acetyl and resin chains.

2. Construction in progress of ¥59.9bn in FY2026, down from ¥79.9bn in FY2024. This is the pipeline of assets that still has to earn a return.

Cash flow

Commentary. Free cash flow after PP&E capex has been thin: a cumulative ¥16.5bn over FY2023–FY2026. In the same period, dividends plus buybacks totaled ¥108.3bn. The gap was funded by cross-shareholding sales (about ¥60.7bn in proceeds), drawdown of cash (from ¥93.5bn to ¥66.8bn) and debt. The weak FY2023 operating cash flow of ¥26.8bn reflects a ¥31.9bn inventory build. Shareholder returns have therefore been partly balance-sheet funded. This is a central tension for Accelerate 2030, which commits at least ¥90bn to returns over FY2027–FY2029.

Ratios

How the derived ratios were calculated.

ROIC: Operating profit × (1 − 30% notional tax), divided by (shareholders' equity + net debt). Daicel's own ROIC figure for 1H FY2026/3 was 4.9%, down 1.8 percentage points.

Cash conversion cycle: Inventory days plus receivable days minus payable days, using year-end balances, cost of sales and net sales.

Dividend payout, FY2022: Calculated as DPS ÷ EPS; it was not disclosed in the retrieved FY2022 document.

Commentary. Returns peaked in FY2024 (ROE 17.1%) and have fallen sharply since. Even before impairments, FY2026 ROIC of about 5% sits below the FY2026 impairment test's 9.8% discount rate for TOPAS. It is also well below the Accelerate 2030 target of ≥10%. Interest coverage halved in FY2026 because interest expense rose 61% to ¥3.2bn as borrowings increased and Japanese rates normalized. A cash conversion cycle of about 170 days is long, and the flagged "asset-light / inventory reduction" agenda in the FY2027/3 outlook directly targets it.

Management guidance and consensus

FY2027/3 guidance calls for:

• sales of ¥595bn (+2.7%);

• operating profit of ¥42.5bn (+1.0%);

• net income of ¥32bn (+214%);

• EPS of ¥125.30 and DPS of ¥70.

Guidance excludes Middle East effects. Q1 delivered 33% of full-year operating profit (¥14.0bn), but the 1H guidance implies a weak Q2. Consensus, as shown by MarketScreener, has FY2027/3 sales growth of about 5% and FY2028/3 sales growth of about 3.5%, with P/E falling from about 11x to about 9.8x. That implies analysts expect EPS growth of roughly 12% in FY2028/3 (indicative, derived).

Bull case

1. The HPP inflection is real. Q1 FY2027/3 HPP sales rose 23.9% and operating profit rose 20.9%, driven by AI-server LCP and the recovery of POM volumes from a tariff-depressed base. HPP is 42% of revenue, so sustained double-digit profit growth there alone could lift group operating profit 10–15% within two years.

2. Normalizing Materials offers large operating leverage. Materials earned ¥42.7bn in FY2024 versus ¥15.0bn in FY2026. Fixing the CO plant (measures in FY2027/3), clearing excess inventory and passing through pulp and raw-material costs could recover a meaningful share of that ¥27.8bn gap.

3. Capital returns and valuation create a floor. The stock trades at about 1.0x book, yields about 4.9%, and the company is committed to DOE ≥5% and a ≥60% total return ratio, on top of a 15% cut in share count since 2023. Any credible progress toward 10% ROIC should trigger a re-rating from about 7x EV/EBITDA.

Bear case

1. Accelerate 2030 targets look unreachable. EBITDA of ≥¥170bn requires about 15% annual growth from ¥85bn, after the prior plan missed its operating-profit target by about half. The quick cut of the growth target from +50% to +30% undermines credibility.

2. Cash generation does not cover the promises. FY2023–FY2026 free cash flow after capex was ¥16.5bn, against ¥108bn of returns. Committing ≥¥90bn in returns plus ≥¥160bn in growth capex depends on achieving the ¥295bn operating cash flow plan, which is about ¥98bn a year versus a ¥66bn average over FY2022–FY2026. Debt or further asset sales may have to fill the gap.

3. Structural pressure on the core cash cows. Management itself expects acetate tow prices to fall in FY2027/3 on local competition. Peers Eastman (Fibers −20%) and Celanese both report tow destocking. Chinese overcapacity is squeezing caprolactone, cellulose acetate and POM, while Middle East disruption adds supply-chain cost.

Catalysts and monitorables (next 12 months)

Concluding analyst verdict

Daicel enters Accelerate 2030 from a cyclical and self-inflicted trough. FY2026/3 operating profit of ¥42.1bn was the lowest in five years. ROE collapsed to 2.9% after a ¥32bn impairment on a German COC plant. The former Accelerate 2025 targets were missed by a wide margin. Yet the franchise underneath is intact. Daicel is Japan's only acetic-acid producer, a top-tier acetate tow supplier, a global engineering-plastics player with exposure to AI-server LCP, and a leading independent inflator maker. It carries an A+ rating, a 43% equity ratio and almost no goodwill.

The investment debate is therefore not about solvency or franchise durability. It is about capital allocation and execution credibility. The early evidence is mixed. On the positive side, the Q1 FY2027/3 print showed HPP operating profit up 21% and Safety volumes up. The Polyplastics absorption removes a layer of complexity. The upgraded shareholder-return policy (DOE ≥5%, ¥70 DPS) gives investors a cash yield near 5% while they wait. On the negative side, free cash flow has not covered shareholder returns for four years. Materials faces tow price erosion and Middle East disruption. The new plan's growth target was trimmed within days of being published.

At about 1.0x book, about 11.5x guided earnings and about 7x trailing EV/EBITDA, the market is pricing Daicel as an ex-growth cyclical. That is plausible but probably too pessimistic if the CO plant stabilizes and HPP momentum holds. Our view is a cautiously constructive, income-oriented stance. The risk–reward is asymmetric to the upside only if 1H FY2027/3 shows Materials stabilizing and management backs its return commitment with a renewed buyback. Absent those signals, the stock is likely to remain a value-trap candidate trading on its yield. The two indicators most worth tracking are FY2027/3 operating cash flow against the ¥98bn annual run-rate the plan requires, and the TOPAS Plant No. 2 timeline.

---

All figures are drawn from public disclosures. Derived figures are arithmetic transformations of reported data, and the method is stated where used.